Post-marketing surveillance framework of cell and gene therapy products in the European Union, the United States, Japan, South Korea and China: a comparative study.
PMID : 39334246 ·
Y, u, x, i, n, , C, a, i, ;, , L, i, j, u, a, n, , S, u, i, ;, , J, i, n, g, j, i, n, g, , W, a, n, g, ;, , W, e, i, l, i, n, , Q, i, a, n, ;, , Y, e, h, e, n, g, , P, e, n, g, ;, , L, u, y, a, o, , G, o, n, g, ;, , W, e, i, j, i, a, , W, u, ;, , Y, u, a, n, , G, a, o
Publicité
Résumé
Cell and gene therapy products (CGTPs) often receive accelerated approvals, lacking comprehensive long-term safety and efficacy data, which can raise significant safety concerns. This research aims to study the post-marketing surveillance (PMS) of CGTPs in the European Union (EU), the United States (US), Japan, South Korea, and China, to offer insights for the development of a secure and standardized post-marketing regulatory framework for CGTPs. Related regulations and the implementation effect
Publicité
Source officielle
Voir sur PubMed →Données issues de PubMed / NCBI. Pour le texte intégral et les informations les plus récentes, consultez toujours la notice officielle.